HERE FOR 20 YEARS FOR PEOPLE WITH AN INTEREST IN MULTIPLE SCLEROSIS Skip to content
0 Members and 0 Guests are viewing this board.
A

(Abst.) Siponimod following alemtuzumab for SPMS...

Started by agate
0Replies
363Views
A
agate
A

Impact of previous DMT on effectiveness, safety outcomes in PwMS treated w/Lemtrada

Started by agate
0Replies
417Views
A
agate
A

(Abst.) Alemtuzumab and rx medication use in the MS population

Started by agate
0Replies
410Views
A
agate
A

(Abst.) Acute cardiotoxicity associated w/alemtuzumab infusion for MS

Started by agate
0Replies
443Views
A
agate
A

(ACTRIMS) Fatal intercerebral hemorrhage secondary to alemtuzumab

Started by agate
0Replies
448Views
A
agate
A

(Abst.) ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for MS

Started by agate
0Replies
435Views
A
agate
A

Refractory chronic spontaneous urticaria after Lemtrada in MS

Started by agate
0Replies
277Views
A
agate
A

(Abst.) Alemtuzumab-induced lung injury in 3 MS patients

Started by agate
0Replies
353Views
A
agate
A

(MS Journal editorial) Emerging safety issues in alemtuzumab-treated MS patients

Started by agate
0Replies
366Views
A
agate
A

EMA to restrict use of alemtuzumab pending review

Started by agate
0Replies
321Views
A
agate
A

Alemtuzumab under scrutiny because of risk of stroke in some patients with MS

Started by agate
0Replies
449Views
A
agate
A

(Abst.) Autoimmune nephropathies after Lemtrada treatment in PwMS

Started by agate
0Replies
347Views
A
agate
A

(Abst.) Immune profiling of a patient w/alemtuzumab-associated PML

Started by agate
0Replies
365Views
A
agate
A

(Abst.) Neutropenia w/fatal outcome in MS patient 23 days after alemtuzumab infusion

Started by agate
0Replies
448Views
A
agate
A

More risks emerge for alemtuzumab in MS

Started by agate
0Replies
371Views
A
agate
A

(Absts.) Two adverse events with Lemtrada reported

Started by agate
0Replies
494Views
A
agate
A

(Abst.) Decreased platelet number in MS during alemtuzumab infusion...

Started by agate
0Replies
437Views
A
agate
A

(Abst.) Activation of MS during Lemtrada therapy in 3 patients w/MS

Started by agate
0Replies
406Views
A
agate
A

(Abst.) Alemtuzumab in MS: Lessons from social media in enhancing patient care

Started by agate
0Replies
477Views
A
agate
A

Induction of new autoimmune diseases after alemtuzumab therapy for MS: Learning from adversity

Started by agate
0Replies
419Views
A
agate